Back to JHPCYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
View Full LandscapeDrug Information
Target Indication
KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting
Clinical Trial
NCT07232875Last updated: 7/21/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
apatinibPhase 3
Non-Small-Cell Lung Cancer
SHR6390Phase 3
Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
SHR-1209Phase 3
Primary Hypercholesterolemia
PyrotinibPhase 3
HER2-positive Breast Cancer
SHR-1210Phase 3
Nasopharyngeal Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts